Ferris, R L <br/><br/>
Durvalumab with or without tremelimumab in patients with recurrent or metastatic head and neck squamous cell carcinoma: EAGLE, a randomized, open-label phase III study.  [electronic resource] 

 -  Annals of oncology : official journal of the European Society for Medical Oncology  07 2020 
 - 942-950 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1569-8041 
<br/><br/><label>Standard No.: </label>10.1016/j.annonc.2020.04.001  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Antibodies, Monoclonal<br/>Antibodies, Monoclonal, Humanized--therapeutic use<br/>Antineoplastic Combined Chemotherapy Protocols--therapeutic use<br/>Head and Neck Neoplasms--drug therapy<br/>Humans<br/>Neoplasm Recurrence, Local--drug therapy<br/>Squamous Cell Carcinoma of Head and Neck--drug therapy